Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Denali Therapeutics Inc.NASDAQ: DNLI
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $36.28M rose 12.4% year over year, behind the +19.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 15 analysts of $50.19M (-48.3%) for the fiscal year ending Dec 2026, a slowdown from the -7.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $36.28M+18.3% QoQ
- Last fiscal yearDec 2025
- $97.1M-7.9% YoY
- LTMJun 2026
- $139.03M+19.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 97.1M USD
- Year-over-year change
- -7.9%
- 4-year CAGR
- +5.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.1M | -7.9% |
| FY2024 | 2024-12-31 | 105.44M | +2.0% |
| FY2023 | 2023-12-31 | 103.35M | +14.2% |
| FY2022 | 2022-12-31 | 90.48M | +14.4% |
| FY2021 | 2021-12-31 | 79.06M | — |
Selling, General & Admin vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 selling, general & admin of $139.03M is the 3rd highest of the 11 companies compared; the peer median is $65.18M.
- Its year-over-year change of +19.2% is the 5th highest of 11, against a peer median of +13.6%.
- Selling, general & admin amounts to 3857.6% of revenue for DNLI, versus a peer median of 116.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.43B | +24.9% | +15.4% | 38.5% | |
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Jun 2026 | $139.03M | +19.2% | +2.4% | 3857.6% | |
| LTM Sep 2026 | $117.61M | +115.1% | -0.3% | — | |
| LTM Jun 2026 | $99.69M | -4.4% | -6.7% | — | |
| LTM Sep 2026 | $74.79M | +15.8% | -20.9% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $55.57M | -17.1% | +24.5% | — |
| LTM Mar 2026 | $47.37M | -20.9% | -4.0% | 257.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M | +37.9% | +181.0% | 171.4% |
| LTM Mar 2026 | $10.32M | -12.0% | -7.1% | — | |
| LTM Jun 2026 | $7.78M | +11.4% | -90.2% | — | |
| Peer median (excluding DNLI) | $65.18M | +13.6% | -2.1% | 116.2% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| Weighted Avg Shares | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
| Weighted Avg Shares (Diluted) | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.